Screener
Repligen RGEN Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Repligen in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The source filing: Repligen’s 10-Q, filed July 29, 2026.
- Filed
- Jul 29, 2026, 4:19 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-323773
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $606,783 | $566,021 |
| Marketable securities | 203,666 | 201,607 |
| Accounts receivable, net of allowances of $3,099 and $2,767 at June 30, 2026 and December 31, 2025, respectively | 157,710 | 158,587 |
| Inventories, net | 186,604 | 170,458 |
| Prepaid expenses and other current assets | 45,791 | 40,712 |
| Total current assets | 1,200,554 | 1,137,385 |
ITEM 1. Financial Statements
FAQ
- What is Repligen's cash & equivalents?
- Repligen (RGEN) reported cash & equivalents of $606.78M in Q2 2026.
- How has Repligen's cash & equivalents changed year-over-year?
- Repligen's cash & equivalents decreased by 14.4% year-over-year, from $708.86M to $606.78M.
- What is the long-term trend for Repligen's cash & equivalents?
- Over 5 years (2020 to 2025), Repligen's cash & equivalents has grown at a -4.6% compound annual growth rate (CAGR), from $717.29M to $566.02M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Repligen's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude